Isomorphic Labs reportedly raises $2.1B Series B

Isomorphic Labs

Isomorphic Labs announced a $2.1 billion Series B led by Thrive Capital, with Alphabet and GV returning and MGX, Temasek, CapitalG and the UK Sovereign AI Fund joining. The funding will power its IsoDDE AI drug design engine, global expansion and its drug candidate pipeline, advancing computational drug discovery beyond protein structure prediction.

• $2.1B Series B led by Thrive Capital; Alphabet and GV returning investors
• New investors: MGX, Temasek, CapitalG, UK Sovereign AI Fund
• Funds will power IsoDDE drug design engine, global expansion, and drug candidate pipeline
• Rounds build on AI drug discovery platform that combines structure prediction with binding affinity and pocket discovery